{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:02:35Z","timestamp":1789718555782,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ygyno.2013.06.011","type":"journal-article","created":{"date-parts":[[2013,6,14]],"date-time":"2013-06-14T04:32:44Z","timestamp":1371184364000},"page":"426-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer"],"prefix":"10.1016","volume":"130","author":[{"given":"William J.","family":"Lowery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlei W.","family":"Lowery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micael","family":"Lopez-Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2013.06.011_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.ygyno.2013.06.011_bb0010","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","article-title":"Management strategies for recurrent platinum-resistant ovarian cancer","volume":"71","author":"Naumann","year":"2011","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ygyno.2013.06.011_bb0015","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","article-title":"Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials","volume":"59","author":"Blackledge","year":"1989","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.ygyno.2013.06.011_bb0020","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"3\u20134","key":"10.1016\/j.ygyno.2013.06.011_bb0025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000328451","article-title":"Second-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study","volume":"80","author":"Bruzzone","year":"2011","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.ygyno.2013.06.011_bb0030","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/IGC.0b013e31820d738c","article-title":"Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study","volume":"21","author":"Crespo","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"16","key":"10.1016\/j.ygyno.2013.06.011_bb0035","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1002\/cncr.25967","article-title":"Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study","volume":"117","author":"McGonigle","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.06.011_bb0040","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.18_suppl.lba5002","article-title":"AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)","volume":"30","author":"Pujade-Lauraine","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2013.06.011_bb0050","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2009.0031","article-title":"NCCN clinical practice guidelines in oncology: palliative care","volume":"7","author":"Levy","year":"2009","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"8","key":"10.1016\/j.ygyno.2013.06.011_bb0055","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1089\/jpm.2011.0217","article-title":"Utilization of supportive and palliative care services among oncology outpatients at one academic cancer center: determinants of use and barriers to access","volume":"15","author":"Kumar","year":"2012","journal-title":"J. Palliat. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2013.06.011_bb0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ygyno.2012.06.025","article-title":"The utilization of palliative care in gynecologic oncology patients near the end of life","volume":"127","author":"Fauci","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2013.06.011_bb0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"33","key":"10.1016\/j.ygyno.2013.06.011_bb0070","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2013.06.011_bb0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/109662101750290191","article-title":"Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital","volume":"4","author":"Lutz","year":"2001","journal-title":"J. Palliat. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2013.06.011_bb0080","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1200\/JCO.2005.12.107","article-title":"Late referrals to specialized palliative care service in Japan","volume":"23","author":"Morita","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2013.06.011_bb0085","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1001\/jama.299.14.1698","article-title":"Effectiveness of specialized palliative care: a systematic review","volume":"299","author":"Zimmermann","year":"2008","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ygyno.2013.06.011_bb0090","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2010.04.014","article-title":"End of life care for women with gynecologic cancers","volume":"118","author":"Barbera","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2013.06.011_bb0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ygyno.2005.07.102","article-title":"Resource utilization for ovarian cancer patients at the end of life: how much is too much?","volume":"99","author":"Lewin","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2013.06.011_bb0100","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","article-title":"Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment","volume":"113","author":"Havrilesky","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2013.06.011_bb0105","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2003.01.104","article-title":"Simultaneous care: disease treatment and palliative care throughout illness","volume":"21","author":"Meyers","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2013.06.011_bb0110","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1001\/jama.292.14.1738","article-title":"Decision making at a time of crisis near the end of life","volume":"292","author":"Weissman","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ygyno.2013.06.011_bb0115","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.suponc.2011.03.003","article-title":"Does palliative care improve outcomes for patients with incurable illness? A review of the evidence","volume":"9","author":"El-Jawahri","year":"2011","journal-title":"J. Support. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2013.06.011_bb0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jpainsymman.2010.03.017","article-title":"Impact of a palliative care consultation team on cancer-related symptoms in advanced cancer patients referred to an outpatient supportive care clinic","volume":"41","author":"Yennurajalingam","year":"2011","journal-title":"J. Pain Symptom Manage."},{"issue":"2","key":"10.1016\/j.ygyno.2013.06.011_bb0125","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.2008.17.7568","article-title":"Phase II study of an outpatient palliative care intervention in patients with metastatic cancer","volume":"27","author":"Follwell","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2013.06.011_bb0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cncr.24017","article-title":"Symptom distress, interventions, and outcomes of intensive care unit cancer patients referred to a palliative care consult team","volume":"115","author":"Delgado-Guay","year":"2009","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2013.06.011_bb0135","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archinternmed.2011.87","article-title":"The optimal delivery of palliative care: a national comparison of the outcomes of consultation teams vs. inpatient units","volume":"171","author":"Casarett","year":"2011","journal-title":"Arch. Intern. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2013.06.011_bb0140","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/PPO.0b013e3181f684e5","article-title":"What is the evidence that palliative care teams improve outcomes for cancer patients and their families?","volume":"16","author":"Higginson","year":"2010","journal-title":"Cancer J."},{"issue":"20","key":"10.1016\/j.ygyno.2013.06.011_bb0145","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.ygyno.2013.06.011_bb0150","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"9375","key":"10.1016\/j.ygyno.2013.06.011_bb0155","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ygyno.2013.06.011_bb0160","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2013.06.011_bb0165","series-title":"AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)","author":"Pujade-Lauraine","year":"2012"},{"issue":"3","key":"10.1016\/j.ygyno.2013.06.011_bb0170","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cncr.22045","article-title":"Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis","volume":"107","author":"Rocconi","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2013.06.011_bb0175","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1200\/JCO.2001.19.5.1266","article-title":"Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer","volume":"19","author":"Doyle","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2013.06.011_bb0180","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa1204410","article-title":"Patients' expectations about effects of chemotherapy for advanced cancer","volume":"367","author":"Weeks","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2013.06.011_bb0185","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2010.05.021","article-title":"Hospice enrollment for terminally ill patients with gynecologic malignancies: impact on outcomes and interventions","volume":"118","author":"Keyser","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2013.06.011_bb0190","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2011.35.7996","article-title":"Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer","volume":"30","author":"Greer","year":"2012","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813008445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813008445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T07:16:07Z","timestamp":1563174967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813008445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0090825813008445"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.06.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}